EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Maintenance Liposomal Doxorubicin Following Induction Doxorubicin in Soft Tissue Sarcoma: A Single-Center Observational Study

Alexandre Da Silva Faco, Mohammad Amin Salehi iD, Mohammad Hassan Hodroj iD, Kaveh Mozafari-Lorestani iD, Feras A Moria, Jonathan Noujaim, Ramy R Saleh iD

Current Oncology · 30.04.2026 · 33 (5) · 260

DOI: 10.3390/curroncol33050260 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Current Oncology, online erschienen am 30.04.2026. Verfasst von Alexandre Da Silva Faco und 6 weiteren Autor:innen. Beteiligte Einrichtung: McGill University Health Centre, Montreal, QC H4A 0B1, Canada. Hauptthemen laut MEDLINE: Doxorubicin, Sarcoma, Antibiotics, Antineoplastic. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Maintenance chemotherapy prolongs progression-free survival (PFS) in several malignancies, but its role in soft tissue sarcoma (STS) remains unclear. Conventional doxorubicin is limited by cumulative toxicities. Liposomal doxorubicin may allow prolonged therapy. We evaluated outcomes of patients treated with maintenance liposomal doxorubicin following induction doxorubicin. This was a single-center retrospective study using the Quebec Sarcoma Registry from 2015 to 2025. Eligible patients had histologically confirmed STS and received doxorubicin-based induction therapy. Those achieving disease control were treated with maintenance liposomal doxorubicin. Clinical variables, adverse events, and outcomes were collected, and PFS and overall survival (OS) were estimated using the Kaplan–Meier method. Twenty-four patients were included (median age 61 years; 62.5% male), with leiomyosarcoma and undifferentiated pleomorphic sarcoma as the most frequent histologies. The median induction exposure was six cycles, and maintenance treatment was administered for a median of five cycles. Median PFS was 11.4 months, and median maintenance PFS was 6.1 months. Infusion reactions and hematologic toxicities were the most common adverse events. Median OS was 60.2 months. Maintenance liposomal doxorubicin was feasible, well-tolerated, and associated with encouraging disease control in selected patients, supporting further prospective evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinSarcomaAntibiotics, AntineoplasticHumansFemaleMaleMiddle AgedRetrospective StudiesAgedAdultPolyethylene Glycols

Stichwörter der Autor:innen

Doxorubicinliposomal doxorubicinmaintenancesoft tissue sarcomasystemic therapy

Substanzen

Doxorubicinliposomal doxorubicinAntibiotics, AntineoplasticPolyethylene Glycols

Autor:innen und Institutionen

  • McGill University Health Centre, Montreal, QC H4A 0B1, Canada.
  • Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  • Hôpital Maisonneuve-Rosemont, Montréal, QC H1T 2M4, Canada.

ORCID-Profile: Mohammad Amin Salehi, Mohammad Hassan Hodroj, Kaveh Mozafari-Lorestani, Ramy R Saleh

Zitieren

APA

Faco, A. D. S., Salehi, M. A., Hodroj, M. H., Mozafari-Lorestani, K., Moria, F. A., Noujaim, J., & Saleh, R. R. (2026). Maintenance Liposomal Doxorubicin Following Induction Doxorubicin in Soft Tissue Sarcoma: A Single-Center Observational Study. Current Oncology, 33(5), 260. https://doi.org/10.3390/curroncol33050260

Vancouver

Faco ADS, Salehi MA, Hodroj MH, Mozafari-Lorestani K, Moria FA, Noujaim J, et al. Maintenance Liposomal Doxorubicin Following Induction Doxorubicin in Soft Tissue Sarcoma: A Single-Center Observational Study. Current Oncology. 2026;33(5):260. doi:10.3390/curroncol33050260

BibTeX
@article{Faco2026,
  author = {Faco, Alexandre Da Silva and Salehi, Mohammad Amin and Hodroj, Mohammad Hassan and Mozafari-Lorestani, Kaveh and Moria, Feras A and Noujaim, Jonathan and Saleh, Ramy R},
  title = {Maintenance Liposomal Doxorubicin Following Induction Doxorubicin in Soft Tissue Sarcoma: A Single-Center Observational Study},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {5},
  pages = {260},
  doi = {10.3390/curroncol33050260}
}
Kostenlos starten →